| 埃罗替尼在非小细胞肺癌治疗中的研究进展 |
| |
| 引用本文： | 岑洪,胡晓桦.埃罗替尼在非小细胞肺癌治疗中的研究进展[J].国外医学(肿瘤学分册),2007(7). |
| |
| 作者姓名： | 岑洪 胡晓桦 |
| |
| 作者单位： | 广西医科大学附属肿瘤医院化疗一科，广西医科大学附属肿瘤医院化疗一科 |
| |
| 摘 要： | 埃罗替尼(erlotinib)是表皮生长因子受体(EGFR)酪氨酸激酶抑制剂,能与细胞内EGFR分子酪氨酸激酶结构域的ATP结合袋特异性结合,可逆性地抑制EGFR酪氨酸激酶活性,促使肿瘤细胞凋亡,抑制肿瘤细胞的增殖、侵袭、血管新生和转移。该药目前已成功用于晚期非小细胞肺癌(NSCLC)的治疗,可显著延长患者的生存时间和无进展生存时间,显著改善症状,改善患者生活质量。
|
| 关 键 词： | 受体，表皮生长因子 癌，非小细胞肺 抗肿瘤药 |
Erlotinib in the treatment of non-small cell lung cancer |
| |
| CEN Hong.Erlotinib in the treatment of non-small cell lung cancer[J].Foreign Medical Sciences (Cancer Section),2007(7). |
| |
| Authors: | CEN Hong |
| |
| Institution: | CEN Hong.Department of Chemotherapy,Guangxi Cancer Hospital of Guangxi Medical University,Nanning 530021,China |
| |
| Abstract: | Erlotinib is epidermal growth factor receptor(EGFR)tyrosine kinase inhibitor that compete for the ATP-binding pocket of EGFR tyrosine kinase in the cytoplasmic taiL Erlotinib inhibits the activity of EGFR tyrosine kinase reversibly,thus induces tumor cells apopotosis,inhibits cellular proliferation,angiogene- sis,tumor invasion,and metastasis.Erlotinib can prolong overall survival and progress free survival in patients with advanced non-small-cell lung cancer,relieve symptoms and improve quality of life. |
| |
| Keywords: | Receptor epidermal growth factor Carcinoma non-small-cell lung Antineoplastic agents |
| 本文献已被 CNKI 等数据库收录！ |
|
